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Abstract
Russia has one of the highest rates of cardiovascular disease in the world. The
International Project on Cardiovascular Disease in Russia (IPCDR) was set up
to understand the reasons for this. A substantial component of this study was
the Know Your Heart Study devoted to characterising the nature and causes of
cardiovascular disease in Russia by conducting large cross-sectional surveys
in two Russian cities Novosibirsk and Arkhangelsk. The study population was
4542 men and women aged 35-69 years recruited from the general population.
Fieldwork took place between 2015-18. There were two study components: 1)
a baseline interview to collect information on socio-demographic characteristics
and cardiovascular risk factors, usually conducted at home, and 2) a
comprehensive health check at a primary care clinic which included detailed
examination of the cardiovascular system. In this paper we describe in detail
the rationale for, design and conduct of these studies.
Keywords
Russian Federation, cardiovascular disease, cross-sectional study,
epidemiology, international comparison
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Introduction
Russia has one of the highest rates of mortality from cardiovascular 
disease (CVD) in the world (see non-communicable disease 
mortality data from the World Health Organisation (WHO)), 
despite an ongoing pattern of decline that began in 2005. In 
2015 the CVD mortality rate was four times higher in Russia 
than in England and Wales or Norway (see Human Cause-of-
Death Database and WHO mortality database). These excep-
tional CVD mortality rates are an important reason for the lower 
life expectancy in Russia compared to other industrial countries 
(70.9 years in 2014; see The Demographic Yearbook of Russia 
2015).
CVD mortality in Russia has a number of specific features that 
pose a challenge to our understanding. In most countries, the 
risk of death from CVD correlates well with levels of estab-
lished risk factors such as smoking, serum cholesterol, blood 
pressure and obesity1. However in Russia, while some of 
the risk of CVD death is explained by conventional risk factors 
such as smoking (in men) and a high prevalence of uncon-
trolled hypertension, some aspects of the cardiovascular risk 
profile of the population do not appear to be high risk1,2. Lipid 
profiles appear to be particularly surprising. Previous stud-
ies dating from 1975–2000 have tended to find relatively low 
risk lipid profiles in Russia compared to Western countries, 
with unexceptional low density lipoprotein (LDL) choles-
terol, higher levels of high density lipoprotein (HDL)3 choles-
terol and more favourable ratios of ApoB/A14 or HDL/total 
cholesterol2,5.
One specific and highly distinctive feature of CVD mortal-
ity in Russia, that it shares with several other countries that 
were previously part of the Soviet Union, is that it has shown 
dramatic fluctuations over the past 30 years. Remarkably, these 
fluctuations parallel those from rates of mortality from acute 
alcohol poisoning6. This suggests that hazardous alcohol drink-
ing in Russia over this period has been one of the main drivers 
of fluctuations in CVD deaths7. However the mechanisms under-
lying this association have not been identified and contrast with 
the dominant literature on alcohol and CVD that has in the past 
tended to be preoccupied with the apparent cardio-protective 
effects of moderate drinking8.
The International Project on Cardiovascular Disease in Russia 
(IPCDR) was set up to throw new light on the high rates of 
premature mortality from cardiovascular disease in Russia. 
The project has four separate but inter-related themes. These 
are: 1) investigating the extent to which the differences between 
Russia and other countries in CVD mortality rates may be 
biased because of differences in the way in which deaths are 
certified and coded; 2) generating improved overviews of trends 
and differences on CVD mortality and established risk factors 
in Russia by bringing together and synthesising already col-
lected data; 3) examining the potential role of the health-care 
system and treatment in contributing to the trends in CVD 
rates within Russia and to differences with other countries; 4) 
characterising the nature and causes of cardiovascular disease 
in Russia by conducting large cross-sectional surveys in two 
Russian cities Novosibirsk and Arkhangelsk. This paper describes 
in detail the rationale, objectives, design and conduct of these 
cross-sectional studies that are collectively known in Russia 
as “Узнай своё сердце” (Know Your Heart).
Rationale
To help uncover the nature and causes of the higher CVD 
mortality in Russia today compared to other countries, it is 
desirable to be able to compare the cardiovascular health of a 
random cross-sectional sample of the Russian population with 
data from an equivalent sample from a country with much 
lower CVD mortality (such as Norway). In this context, car-
diovascular health refers to objectively measured aspects of the 
structure and function of the cardiovascular system (such as 
echocardiography derived indices), blood and urine derived 
biomarkers and behavioural risk factors. This detailed informa-
tion may be thought of as the cardiovascular phenotypic pro-
file of a population. The assumption underlying this approach is 
that the future CVD event rates in the surveyed populations in 
Russia will be appreciably higher than the event rates found in 
the population surveyed in the lower mortality country. If this 
is true, then these future differences should be prefigured in 
differences in the cardiovascular phenotypic profile. Iden-
tifying the principle differences in the phenotype between 
Russia and a lower mortality country will throw light on the 
drivers of these differences. Aside from the international 
comparisons, information on the cardiovascular phenotype of a 
sample of the Russian population today will also be valuable for 
understanding the distribution and determinants of CVD within 
Russia, including socio-economic differences, use of health 
systems, treatment and the potential role of particular risk 
factors including alcohol.
            Amendments from Version 2
In response to the third reviewer’s comments we have made the 
following changes:
•    Map showing the location of the cities has been added 
(Figure 2).
•    We have added cIMT and plaque as areas of special 
interest alongside left ventricular ejection fraction.
•    Discussion on the possibilities for follow up has been 
added to the discussion section.
Additional changes:
•    Correction of error in description of the analytic methods 
for LDL cholesterol from Immuno-inhibition Enzymatic Color 
Test to Enzymatic Color Test
•   Highlighted the study website is now active
•    Small editorial changes to questionnaires (Supplementary 
File 3)
See referee reports
REVISED
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Protocol
Objectives
The objectives of the cross-sectional studies conducted as part 
of the fourth component of the IPCDR study were as follows: 
1)    To characterise the CVD phenotypes of the Russian 
population samples, including in depth objec-
tive measures of cardiac and vascular structure and 
function, laboratory-derived biomarkers from biologi-
cal samples and behaviours including risk factors as well 
as health service use;
2)    Determine the extent to which the CVD phenotypes 
in two Russian cities, Arkhangelsk and Novosibirsk 
differ from those seen in other countries, and to identify 
whether any such differences may plausibly explain the 
excess of CVD mortality seen in Russia. In particular 
comparisons will be made with the 7th wave of the Tromsø 
Study in Norway conducted in 2015–16. Key aspects of 
the protocol of the medical examination were aligned 
in order to be able to make direct comparisons. These 
comparisons are being taken forward under the “Heart 
to Heart” initiative established jointly with UiT, The 
Arctic University of Norway.
3)    Investigate the associations of these CVD phenotypes with 
socio-demographic factors, health behaviours including 
alcohol use and known cardiovascular risk factors 
within Russia in order to improve understanding 
of the determinants of these phenotypes;
4)    Undertake exploratory studies of the association of 
gut microbiota with behaviours (especially heavy 
drinking) and the CVD phenotypes.
The key associations and comparisons of interest are shown in 
Figure 1. Examples of the types of data collected on cardiovascular 
phenotype are shown in Table 1.
Sample size calculation
The original target sample size was determined based on both 
the power needed to make comparisons with other population 
based studies and to investigate associations of interest 
within the Know Your Heart Study. For example, if we wished to 
compare the prevalence of a binary ECHO phenotype between 
Know Your Heart (N=4500) with a smaller study with data 
available on this phenotype for N=1500 (e.g. the UK 1946 
National Birth Cohort study) we would have 80% power to detect 
an odds ratio of 1.4 significant at an alpha of 0.01 assuming 
a prevalence in the smaller study of 10%. Comparisons with 
the larger Tromsø 7 study will be even more powerful. Within 
the Know Your Heart Study we estimate that we will have 80% 
power to detect an OR of 1.6 or more between the top and 
bottom 20% of a continuous exposure variable (e.g. levels of a 
particular lipoprotein entity) and a binary CVD phenotype 
with a prevalence of 10% in the lowest group, that is significant 
with an alpha of 0.01. We are aware that applying many statisti-
cal tests can lead to false-positive correlations / associations, 
and we propose to apply stringent significance cut-offs 
(less than the nominal 0.05) to be determined through data 
simulation (e.g. permutation), complemented by a false discovery 
Figure 1. Key associations and comparisons of interest.
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Table 1. Examples of data available on different aspects of cardiovascular phenotype.
Cardiovascular phenotypes
Type Source Biomarker/proxy measure
Arteriosclerosis/ 
Atherosclerosis
Questionnaire Previous Myocardial Infarction
ECG Evidence of previous Myocardial Infarction
Carotid ultrasound Carotid Intima Media Thickness, plaque
Vicorder Pulse wave velocity
Cardiac remodelling Blood samples B-type natriuretic peptide, High sensitivity Troponin T
Echocardiography Myocardial function and size
Arrhythmia ECG Baseline rhythm
rate approach. While these sample size calculation are based on 
estimates for a range of plausible scenarios it should be noted that 
the study may be under powered for the investigation of some 
associations of interest.
Target population and study setting
We undertook identical cross-sectional studies of clinical 
and life style factors in two Russian cities (Arkhangelsk and 
Novosibirsk) in the period 2015–18 with a target sample size 
of 4500 adults. These cities were chosen as they had a previous 
track-record of conducting large population-based epidemio-
logical surveys and thus could be expected to conduct complex 
research to a high standard2,9–12. The target population was men 
and women aged 35–69 years. This is the age group in which in 
relative terms mortality from cardiovascular disease and many 
other conditions is much higher than in Western countries.
The location of the cities is shown in Figure 2. The city 
of Novosibirsk, in Western Siberia, has a population 
of more than 1,500,000 people and is the third largest city 
in Russia, after Moscow and Saint Petersburg. Arkhangelsk, 
located in the North of European Russia, is a smaller city 
with a population of about 350,000 people. Levels of cardio-
vascular mortality vary across Russia. In the period 2012–16, 
mortality from total circulatory disease at ages 35–69 years 
among the urban population of Novosibirsk region was slightly 
lower than the national average, while in the urban population of 
Arkhangelsk region it was above the national average (Table 2). 
Mortality from ischaemic heart disease was above the national 
average in both cities. Mortality rates from total circulatory dis-
ease and ischaemic heart were considerably higher in Russia 
and in both of the Russian cities compared to Tromsø and Norway 
overall.
The age and education distribution of the populations of 
Novosibirsk and Arkhangelsk compared to the total Russian 
urban population, according to 2010 census data, are shown in 
Figure 3 and Figure 4. The age distribution was similar to the 
national average in both cities but the proportion of people 
with higher education was higher in Novosibirsk.
Study design
The study had two components: 1) a baseline interview to 
collect information on socio-demographic characteristics and 
cardiovascular risk factors, usually conducted at home, and 2) a 
subsequent comprehensive health check at a primary care clinic 
(polyclinic) which included examination of the cardiovascular 
system. An overview of the study design is shown in Figure 5.
Recruitment of Participants from the general population. 
Within each city four districts were selected for the recruitment 
of participants. In Arkhangelsk these were Lomonosovsky, 
Maymaksansky, Mayskaya Gorka and Oktyabrsky. In 
Novosibirsk these were Dzerzinsky, Kirovsky, Leninsky and 
Oktyabrsky. The districts were selected purposefully (not through 
random sampling) to represent a range of socio-demographic 
and mortality levels in each city. A sampling frame of people 
within each district using information on age and sex of occu-
pants at individual addresses was provided by the regional health 
insurance funds. Because of data protection regulations, the 
study team was not provided with individual names. From the 
sampling frames we selected at random addresses to visit 
stratified by age (in 5-year bands), sex and district. The aim was 
to recruit equal numbers of participants in each sex and 5-year 
age group in the city as a whole.
Participants were recruited to the study by home visits carried 
out by trained and experienced interviewers from a local 
commercial survey company. They attempted to identify a person 
of the correct age and sex who, according to the sampling frame, 
should be living at the selected addresses. If the participant 
was not available on the first visit addresses were visited a 
minimum of two more times at varying times of day and at 
weekends. At the end of a successful interview participants 
were invited to attend the health check at a polyclinic and 
if they agreed an appointment was made for them straight 
away using an online calendar.
To maximize the probability of participants agreeing to take 
part in the study information campaigns were conducted in both 
cities. The campaigns were implemented on the assumption 
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Table 2. Mortality rates by sex and cause (age standardized/100,000) for Russia and the urban populations of Arkhangelsk 
and Novosibirsk oblasts and Norway as a whole and the municipality of Tromsø, Norway, aged 35–69 for years 2012–16.
Cause of 
death
Men Women
Russia Arkhangelsk (urban)
Novosibirsk 
(urban) Norway Tromsø* Russia
Arkhangelsk 
(urban)
Novosibirsk 
(urban) Norway Tromsø*
All 
circulatory 
diseases**
735 821 711 89 75 239 245 236 33 19
Ischaemic 
heart 
disease***
407 517 447 49 36 111 125 124 12 7
All causes 1755 1852 1772 410 393 619 612 610 267 157
Notes:
Rates age standardized to 1976 Standard European Population
Data for Russia, Arkhangelsk and Novosibirsk from the Russian Fertility and Mortality database of the Centre of Demographic Research of the New 
Economic School http://www.demogr.nes.ru/index.php/en/demogr_indicat/data
Data for Norway and Tromsø provided by Section of Health Data and Digitalisation, Norwegian Institute of Public Health
* Rates for municipality of Tromsø (90% of population living in the urban area of the city) are based on only 318 all cause deaths for men and 184 all 
cause deaths for women. Numbers of deaths from IHD are 30 for men and 8 for women. To indicate their associated imprecision they are shown in 
italics.
** ICD 10 codes I00-I99 (Diseases of the circulatory system)
***ICD 10 codes I20-I25 (Ischemic Heart Diseases)
Figure 2. Location of Arkhangelsk, Novosibirsk and Tromsø.
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Figure 3. Age profile of Novosibirsk and Arkhangelsk compared to the Russian Urban Population from the 2010 Russian census for men (a) 
and women (b).
that if people had previously heard that the study was legitimate 
and important through the media they would be more likely to 
participate. Special consideration was given to the name of 
the study used for participants “Know your heart” (in Russian 
“Узнай своё сердце”), the study logo and the visual style of 
study materials. We used focus groups with the general public 
to guide the final design. The information campaign included 
production of two short films about the study (one for each 
city) which were shown regularly on TV throughout the period 
of the study (Supplementary File S1). In addition, news 
items about the study progress, and the experience of par-
ticipants who had taken part in the study were periodically 
disseminated on TV, radio and in print media. Large bill board 
advertisements about the study were also placed on rotation 
throughout the city at bus stops, super markets and areas where 
advertisements were concentrated in the city (Supplementary 
File S2). These activities were more intensive and consistent 
in Arkhangelsk than in Novosibirsk.
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Figure 4. Educational Profile of Novosibirsk and Arkhangelsk (35–69 years) compared to the Russian urban population from the 2010 
Russian census.
Recruitment of participants from the general population started 
in November 2015 and finished in December 2017. Recruit-
ment paused at Christmas and over the summer (July and 
August) in keeping with Russian holidays when participants 
were likely to leave the city.
Recruitment of participants receiving treatment for alcohol 
problems. Given the potential importance of hazardous alcohol 
use as a risk factor for cardiovascular disease in Russia, an 
additional 275 participants aged 35–69 years with a primary 
diagnosis of alcohol problems were recruited from Arkhangelsk 
Regional Psychiatric hospital. Where possible, participants were 
recruited from the same four districts of the city as the general 
population sample. By using a clinical facility as a source 
of participants we were aware that we would be recruiting a 
highly selected group of heavy drinkers. However, our aim 
was to be able to characterize the cardiovascular phenotype in a 
group of heavy drinkers per se.
Participants were recruited by clinical staff at the hospital 
at least one week after admission in order to ensure that the 
acute detoxification stage of treatment was complete and 
they were not suffering from alcohol withdrawal. The same 
interviewers involved in the general population study visited 
participants at the hospital and administered a shortened version 
of the baseline questionnaire with some supplementary questions 
on alcohol use included to obtain more detailed characterization 
of drinking behaviour in this sub-group (Supplementary File 3). 
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Figure 5. Study Design (Main population survey).
The day after their interview, participants were provided with 
free transport to attend the health check. The health check 
took place in the same polyclinic as for the general popula-
tion survey, but to avoid placing an excessive burden on the 
participants, the health check itself was shortened by dropping 
a few of the more onerous aspects of the examination: pulse 
wave velocity, physical function tests, spirometry, and use of 
the Actiheart devices to measure physical activity continuously 
over a period of days.
Recruitment of and examination of participants for this sub-study 
began in January 2017 and ended in October 2017.
Repeatability study. In each city approximately 200 partici-
pants from the general population sample (397 participants 
in total) were re-interviewed and had a repeated health check 
one year after their initial health check. The main aim was 
to estimate correction factors that can be used to correct for 
measurement error during the analysis stage, specifically 
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when regressing an outcome on a single continuous predictor 
variable that is measured with error (i.e. to correct for regres-
sion dilution bias). The time period of one year was chosen to 
minimize the effects of seasonal variation on within-person 
variability. A secondary aim of the repeatability study was 
to investigate reproducibility of those characteristics that by 
definition should not change, such as educational level, whether an 
ever smoker and drinker, and so on.
Fieldwork outcomes
General population sample. The study recruited 5089 par-
ticipants for the baseline interview of whom 4542 participants 
went on to attend a health check. Of these 4542 participants, 
2381 were from Arkhangelsk (41.5% male) and 2161 were 
from Novosibirsk (42.0% male). The median age of partici-
pants from Arkhangelsk was 54 years (IQR 45–62) and from 
Novosibirsk 56 years (IQR 47–64) with a higher percentage of 
participants in the older age categories in Novosibirsk than 
Arkhangelsk.
Response percentages were calculated from individual level 
data on the outcome of every visit made to each address. A 
list of the codes used to classify the outcome of the visits is 
provided in Supplementary Table S1 (Supplementary File 4). 
Three types of response percentages were defined based on the 
denominator used:
Type 1: The denominator was all households in the sampling 
frame where an attempt was made to contact a participant. This 
is the most conservative estimation of response percentage.
Type 2: The denominator excluded addresses which were 
found to be invalid or where no participant of the correct age 
or sex was living. These exclusions are largely accounted for 
by the original sampling frame being out of date or inaccurate.
Type 3: The denominator was restricted to addresses where it 
was determined that an eligible participant of the correct age 
and sex lived there. This response percentage reflected the 
willingness and ability of households to engage and the skill of 
the interviewer in motivating them to do so. The primary reason 
for non-response here was mainly a refusal to take part.
The response percentages with respect to obtaining a baseline 
interview for each city by age and sex are shown in Table 3. 
The overall response percentages for both cities were: Type 1 
28.1% Type 2 35.1% and Type 3 51.0%. For all types, percent-
ages were higher in Arkhangelsk than Novosibirsk, in women 
compared to men, and among older compared to younger 
participants.
One way of judging the extent of sampling bias introduced 
by non-response is to compare the educational distribution of 
those with a baseline interview and health check with the edu-
cational distribution for each city as determined at the 2010 
Russian Census. Table 4 shows the observed distribution against 
the expected distribution from the Census distribution using 
indirect standardisation for age and sex for both complet-
ing the baseline interview and attending the health check. For 
Arkhangelsk the ratio overall for completing baseline question-
naire was 0.98 and that for attending the health check was 0.99. 
However, younger participants were more likely than expected 
to have higher education and older participants were less likely 
than expected to have higher education. For Novosibirsk the 
ratio of observed to expected education was above 1 for both 
completion of the baseline interview (1.14) and attending 
the health check (1.26).
Not everybody who had a baseline interview had a subsequent 
health check. Some people elected not to have one, while 
others were unable to arrange a suitable time or failed to attend 
at an arranged time. These proportions varied by city, with 
96% attending in Arkhangelsk, but only 83% in Novosibirsk. 
The proportions of interviewed participants by age and sex 
for each city are shown in Table 5. The response percentages 
with respect to health check attendance using the three types of 
response are shown in Supplementary Table S2 by age, sex and 
city (Supplementary File 4). As with response percentages for 
the baseline interview these were higher in Arkhangelsk and 
among women and older people.
There is evidence that those who did not attend the health 
check were different to those who did. The associations of 
characteristics measured at baseline with not subsequently 
having a health check are shown in the form of odds ratios in 
Supplementary Table S3 (Supplementary File 4). Adjusting 
simultaneously for city, age, sex, and education and distance 
from the clinic, those who did not have a the health check were 
more likely to be younger, male, with lower educational level, 
not in regular paid employment, have a worse financial situa-
tion, problem drinkers, smokers and report symptoms of major 
depression. Those who self-reported a history of hypertension, 
high cholesterol, myocardial infarction, heart failure or angina 
were more likely to have a health check but those who with 
self-reported previous stroke were less likely to do so. Participants 
living further away from the clinic were also less likely to 
attend the health check.
Patients receiving treatment for alcohol problems. In total 
275 participants receiving treatment for alcohol problems were 
recruited from Arkhangelsk out of 322 patients invited to take 
part (85.4%). It should be noted that although clinicians were 
instructed to invite all eligible participants they were allowed 
to use their clinical judgement as to who should be approached, 
as the patient’s well-being was considered paramount. 
However this sample was not intended to be representative of all 
patients receiving treatment for alcohol problems in Arkhangelsk 
but to obtain a sample of people who drank extremely heav-
ily. The sample was predominantly male (76.4% men) and the 
age distribution was skewed toward younger aged participants 
(median age 47 IQR 41–55).
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Table 4. Ratio of observed to expected (based on 2010 census) participants with higher 
education by age.
Age group Arkhangelsk 
Interviewed
Arkhangelsk 
Health Check
Novosibirsk 
Interviewed
Novosibirsk 
Health Check
Ratio 95% CI Ratio 95% CI Ratio 95% CI Ratio 95% CI
35–39 1.32 1.10, 1.57 1.35 1.12, 1.61 1.28 1.07, 1.53 1.43 1.15, 1.75
40–44 1.30 1.11, 1.51 1.32 1.12, 1.53 1.00 0.83, 1.20 1.12 0.91, 1.36
45–49 1.26 1.06, 1.48 1.28 1.08, 1.50 1.17 1.00, 1.37 1.29 1.08, 1.53
50–54 1.07 0.90, 1.27 1.11 0.93, 1.32 1.35 1.15, 1.57 1.42 1.19 1.68
55–59 0.82 0.67, 0.99 0.82 0.68, 0.99 1.14 0.96,1.35 1.13 0.93, 1.36
60–64 0.66 0.54, 0.81 0.66 0.53, 0.80 1.02 0.87,1.19 1.07 0.89, 1.27
65–69 0.70 0.58, 0.83 0.71 0.59, 0.84 1.08 0.93, 1.26 1.38 1.18, 1.60
All ages 0.98 0.92, 1.04 0.99 0.93, 1.06 1.14 1.07, 1.21 1.26 1.17, 1.34
Data collection
Ethical Approval and Consent. Ethical approval for the 
study was received from the ethics committees of the London 
School of Hygiene & Tropical Medicine (approval number 
8808 received 24.02.2015; for sub-study involving patients 
in treatment for alcohol problems approval number 12018; 
received 11/01/2017), Novosibirsk State Medical University 
(approval number 75 approval received 21/05/2015), the 
Institute of Preventative Medicine (no approval number ; approval 
received 26/12/2014), Novosibirsk and the Northern State Medi-
cal University, Arkhangelsk(approval number 01/01-15 received 
27/01/2015; for sub-study involving patients in treatment 
for alcohol problems approval number 05/11-16 received 
02/11/2016).
Signed informed consent was obtained both at baseline interview 
and at the health check. At baseline interview the consent 
was obtained for passing on name, address, and telephone 
number to the polyclinic medical team for those deciding 
to have a health check. Agreement for interview per se was 
obtained verbally. At the health check written informed consent 
was obtained for participation in the study. Participants were 
given the option also to consent to be re-contacted by the study 
team in the future.
Baseline Interview. At the baseline interview, a questionnaire 
was administered by a trained interviewer using a computer 
assisted personal interviewing device (CAPI) implemented on 
a tablet computer. For quality assurance purposes these devices 
were programmed so both location of the interview (using GPS) 
and the time taken for each question were recorded automati-
cally. The topics covered at the interview are summarised in 
Table 6. Where appropriate we used established and validated 
questions or question sets, as indicated in Table 6. The interview, 
which took a median of 36 minutes (IQR 30.9-44.2 minutes), 
included sections on socio-demographic factors, physical 
activity, physical health (including health service use and 
adherence to medications for hypertension and hypercholeste-
rolemia), various measures of self-reported health including the 
Short-Form 12 health survey (SF-12)13, depression symptoms 
using the Patient Health Questionnaire 9 (PHQ-9) and anxiety 
symptoms using the Generalized Anxiety Disorder 7 (GAD-7) 
both from the Patient Health Questionnaire14, diet quality 
score15, smoking, household structure and socio-economic 
circumstances, and psychosocial factors and life events16,17. 
The questionnaire included particularly detailed questions on 
alcohol use including standard questions on the frequency 
and usual quantity of beverage alcohols (designed for and 
previously used in Russia18), frequency of acute dysfunctional 
drinking behaviours such as hangover and excessive drunken-
ness, period of continuous drunkenness lasting 2 or more days 
during which a participant is withdrawn from normal life (known 
in Russian as zapoi) and the CAGE score for detecting 
problem drinking19.
Health Check examination. The health check included a ques-
tionnaire and a physical examination. All aspects of the health 
check were specified in detail in the form of standard operat-
ing procedures. The whole health check took an average of 
approximately three hours. The questionnaire was adminis-
tered by either a nurse or a cardiologist. It included questions 
on past medical history including previous diagnoses of 
breathlessness measured using the Medical Research Council 
Breathlessness Scale20 and the short form of the Rose 
Angina questionnaire21. Participants were asked to bring all 
their medications with them to the health check including 
inhalers (although only 27% of participants did so) and names 
and doses used per day were recorded. A maximum of 7 
medications were recorded for each person. Women were asked 
questions about their pregnancy history including history of 
gestational diabetes and hypertension, and their use of hormone 
replacement therapy. Hazardous alcohol use was assessed 
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Table 7. Summary of physical examinations components.
Measurement Device or equipment used Comments on protocol
Percent of participants 
attending health check 
with data collected*
Blood pressure
OMRON 705 IT automatic blood 
pressure monitors (OMRON 
Healthcare)39
Three measurements of sitting blood 
pressure taken 2 minutes apart. 98.9%
Pulse Oximetry
Nonin Onyx II 9550 non-invasive 
finger tip pulse oximeters (Nonin 
Medical Inc, USA)
99.7%
Weight and body 
composition
TANITA BC 418 body composition 
analyser (TANITA, Europe GmbH)
Weight only (not body composition) 
measured in participants with pacemaker, 
pregnant or refused
98.1% with body 
composition data
Height Seca® 217 portable stadiometer (Seca Limited) Two measurements 99.9%
Hip and waist 
circumference
Seca measuring tapes (Seca®201) 
(Seca Limited) Two measurements 99.9%
Grip strength JAMAR® digital hand dynamometers (Patterson Medical, UK)
Three measurements per hand in accordance 
with the Southampton protocol38 96.9%
Chair stands - Time taken to stand up and sit down from a chair ten times 97.3%
Standing balance - Time standing on one leg 1)with eyes open and 2)eyes closed 97.3%
Digital ECG Cardiax devices (IMED ltd, Hungary) 99.8%
Pulse wave velocity and 
pulse wave analysis
Non-invasive Vicorder devices 
(Skidmore Medical Ltd, UK)40
Three measurements taken 1 minute apart. 
If the measurements were greater than 
0.5m/s apart or there were concerns about 
record quality further measurements (up to 
7) were taken
99.5%
Vascular ultrasound 
and echocardiography 
examination
GE VividQ machines (GE Health care) In accordance with a strict protocol 99.5%
Energy expenditure over 
5 days
Actiheart (CamNtech Ltd, 
Cambridge, UK)
Offered to approximately 50% of participants. 
Participants who agreed to this component 
of the study took part in a 200m walking test 
first for calibration purposes.
21.6%
Spirometry 6800 pneumotrac spirometers (Vitalograph®, UK)
Offered to approximately 50% of participants. 
Three measurements were taken. If less 
than two acceptable measurement taken 
additional measurements could be taken up 
to a maximum of eight.
45.7%
* Denominator all main study participants where health check was completed
using the Alcohol Use Disorder Identification Test (AUDIT)36. 
Baseline interview questions on smoking were repeated.
A summary of the components of the physical examination 
including the devices used for measurement is shown in Table 7. 
Briefly the physical examination included measurements of 
blood pressure, pulse oximetry, anthropometry (height, waist 
and hip circumference, weight and body composition), digital 
ECGs, pulse wave velocity and pulse wave analysis. Physical 
function was assessed through measurement of grip strength 
using the Southampton protocol38, the time taken to stand up and 
sit down from a chair ten times in line with the MRC National 
Survey of Health and Development Protocols35, and stand-
ing balance on one leg with eyes open and eyes closed using 
protocol from the National Health and Aging Trends Study (Funded 
by the National Institute of Aging (U01AG032947); 2011).
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The clinics were requested to offer 50% of the participants 
lung function tests and the option to wear a combined heart 
rate and movement sensor (Actiheart, CamNtech Ltd, UK) 
on the chest for 5 days in order to provide an objective meas-
ure of physical activity41. Those wearing the monitor were 
asked to complete a 200m self-paced walk test for the purposes 
of individual calibration of the heart rate response42. This 
approach was recently found to be valid for estimating free- 
living activity energy expenditure43. For practical reasons, the 
selection of participants to be offered these additional compo-
nents was done on the basis of offering them to all participants 
on days when medical personnel trained in these procedures 
were working in the clinic. The days of the week these 
procedures were offered on varied throughout the course of the 
fieldwork and included weekends.
Vascular ultrasound and echocardiography examination were 
done in accordance with a very detailed protocol. Participants 
underwent transthoracic echocardiography (ECHO) in the 
left lateral decubitus position using a commercially available 
systems equipped with a 1.0 ~ 5.0 MHz matrix sector transducer 
(Vingmed Vivid q or E9, GE Healthcare, Horten, Norway). A 
common standard operational procedure (SOP) for ECHO was 
developed for the study by an international team of nine lead-
ing experts (including AR, SM, HS, AH, DL) which was used 
in the Know Your Heart (Russia) study and in the Tromsø 7 
(Norway) study. ECG-gated M-mode and two-dimensional 
grey-scale images as well as pulsed, continuous and colour 
Doppler data were acquired in the parasternal and apical views 
with breath hold to ensure image quality. Gray-scale images 
were obtained with only one focal zone to ensure a frame rate 
of at least 50 frames per second.
Images were recorded digitally in cine-loop format or still 
images as appropriate and analysed off-line with commercial 
software EchoPAC (v.113, GE-Vingmed AS, Horten, Norway). 
Off-line ECHO analysis was performed by 1 investigator (MS) 
for images obtained in Norway (Tromsø 7 study) and by the 
central reading laboratory in Novosibirsk by 2 investigators 
(AR, SM) for images obtained in Russia. Left ventricular (LV) 
and atrial volumes were measured from the apical 2- and 
4-chamber views and LV ejection fraction (LVEF) calculated 
using the biplane Simpson’s technique44. LV mass and relative 
wall thickness (RWT) were estimated from M-mode recordings 
according to current recommendations44. Chamber volumes and 
LV mass were indexed to body surface area. Doppler measure-
ments of aortic, mitral, pulmonary and tricuspid valve flow were 
obtained according to current guidelines and the recom-
mended grading of any detected valvular heart disease were 
followed45,46. We evaluated global longitudinal strain and strain 
rate of LV by 2D speckle tracking technique. PW Doppler 
tissue velocities of mitral annulus were traced for additional 
quantification of systolic and diastolic ventricular function45. 
Intra- and inter-reader variability was regularly assessed within 
both reading laboratories and between the Russian and Norwegian 
reading teams.
Vascular ultrasound (VUS) of carotid arteries was conducted 
in accordance with the study SOP for VUS with the 
participant in a supine position using a commercially available 
system equipped with a 3~13 MHz linear transducer (Vingmed 
Vivid q or E9, GE Healthcare, Horten, Norway). ECG-gated 
high-resolution two-dimensional grey-scale images were 
obtained in longitudinal and transverse views. The highest probe 
frequency was applied with only 1 focal zone and the highest frame 
rate (at least 40 frames per sec). VUS images were recorded 
digitally in cine-loop format or still images and analyzed 
off-line with software EchoPAC (v.113, GE-Vingmed AS, Horten, 
Norway).
Off-line vascular analysis was performed by 2 investigators 
(AR, SM) in the reading laboratory in Novosibirsk, Russia. 
Computer-assisted measurement of both common carotid arter-
ies intima-media thickness and assessment of carotid plaques 
(Mannheim Consensus; 2004-2006-2011) and patterns of artery 
wall structure were conducted. Intra- and inter-reader variability 
was regularly assessed.
All participants were asked to give a blood sample. Since 
the health checks took place throughout the day it was not 
considered feasible to ask participants to fast for 12 hours but 
participants were asked to fast for 4 hours prior to attending the 
health check. Questions about time of last meal and drinks 
consumed in the past four hours including caffeine and con-
sumption of alcohol in the past 24 hours were asked by the 
receptionist on arrival and these data were recorded.
Blood samples were collected in 4 SST II vacutainers (8.5ml) 
and 2 EDTA vacutainers (10ml and 6ml) BD® (Beckton, 
Dickinson and Company, Preanalytical Systems, US). Serum 
vacutainers were left at room temperature for 30 minutes 
and then stored at 4°C while EDTA vacutainers were stored 
immediately at 4°C. The 10ml EDTA tube and the 4 SST tubes 
were centrifuged in cooled centrifuges at 4°C at 2100–2200g 
for 15 minutes. Samples were aliquoted in to 1.8 ml Nunc® 
cryotubes® (10 cryovials of serum, 3 cryovials of plasma and 4 
cryovials of whole blood). We aimed for processing, aliquoting 
and freezing of blood samples within a target of 2 hours after 
sample collection (using time stamps from modules used within 
the laboratories at time of sample processing we confirmed 
this this was achieved for 84% of samples: 100% of samples in 
Arkhangelsk and 63% of samples Novosibirsk). Vacutainers and 
cryovials were uniquely identified using bar-coded labels.
Participants were asked to volunteer a spot urine sample and 
faecal samples for analysis of the gut microbiome. Those 
who agreed were provided with appropriate collection kits 
and instructions and requested to provide samples while they 
were in the clinic, or to return samples to the clinic later. The 
proportion of participants providing both types of optional 
sample was considerably higher in Arkhangelsk (urine 59%, 
faecal 43%) than in Novosibirsk (urine 26%; faecal 9%) and was 
particularly high for the participants recruited from alcohol 
services (urine 99.6%; faecal 89%). If providing the sample 
at home participants were instructed to store samples at 4°C 
and return to the clinic within 18 hours in order to meet target 
of freezing samples within 24 hours.
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Table 8. Core set of biological analyses on blood and urine sample.
Target Specific measures Biological sample Method Technology used for analysis
Lipids Total cholesterol Serum Enzymatic Color Test AU 680 Chemistry System Beckman Coulter
High Density Lipoprotein 
Cholesterol (HDL)
Serum Enzymatic Color Test AU 680 Chemistry System Beckman Coulter
Low Density Lipoprotein 
Cholesterol (LDL)
Serum Enzymatic Color Test AU 680 Chemistry System Beckman Coulter 
Triglycerides Serum Enzymatic Color Test AU 680 Chemistry System Beckman Coulter
Apolipoprotein A1 Serum Immuno-turbidimetric Test AU 680 Chemistry System Beckman Coulter
Apolipoprotein B Serum Immuno-turbidimetric Test AU 680 Chemistry System Beckman Coulter
Lp(a) Serum Particle Enhanced 
Immunoturbidimetric Test 
AU 680 Chemistry System Beckman Coulter
Renal function Creatinine Serum Kinetic Color Test (Jaffe) AU 680 Chemistry System Beckman Coulter
Cystatin C Serum Particle Enhanced 
Immunoturbidimetric Test 
AU 680 Chemistry System Beckman Coulter
Albumin Urine Immuno-turbidimetric Test AU 680 Chemistry System Beckman Coulter
Creatinine Urine Kinetic Color Test (Jaffe) AU 680 Chemistry System Beckman Coulter
Inflammatory 
markers
High sensitivity C 
Reactive Protein (CRP)
Serum Immuno-turbidimetric Test AU 680 Chemistry System Beckman Coulter
Iron Pathways Transferrin Serum Immuno-turbidimetric Test AU 680 Chemistry System Beckman Coulter
Metabolites HbA1c Whole blood 
(EDTA)
Immuno-turbidimetric Test AU 680 Chemistry System Beckman Coulter
Liver function 
tests
Gamma glutamyl 
transferase (GGT)
Serum Kinetic Color Test (IFCC) AU 680 Chemistry System Beckman Coulter
Aspartate Transanimase 
(AST)
Serum Kinetic UV-Test P5P activated 
(IFCC)
AU 680 Chemistry System Beckman Coulter
Alanine Transanimase 
(ALT)
Serum Kinetic UV-Test P5P activated 
(IFCC)
AU 680 Chemistry System Beckman Coulter
Cardiac 
micronecrosis
High sensitivity Troponin T Serum The electrochemi-luminescence 
immunoassay “ECLIA”
Cobas e411 analyser (Roche Diagnostics 
GmbH, Hitachi, Japan)
NT-Pro-B type Natriuretic 
Peptide (Nt-Pro-BNP)
Serum Cobas e411 analyser (Roche Diagnostics 
GmbH, Hitachi, Japan)
Alcohol 
biomarker
Carbohydrate Deficient 
Transferrin (CDT) 
(Subset 2500 
Participants)
Serum Capillary Electrophoresis, 
CAPILLARYS-2 
Capillarys automatic capillary 
electrophoresis system (CAPILLARYS-2), 
Sebia S.A., France.
Blood, urine and faecal samples were initially processed 
and stored at -20°C for a maximum of three weeks and then 
transferred to -80°C freezers. Periodically throughout the study 
biological samples were shipped to Moscow and stored at -80°C. 
Analysis was performed in one period at the end of the study 
with samples from both sites analysed in parallel and not 
sequentially. The core set of biochemistries analysed using the 
blood and urine samples are listed in Table 8. The target and 
achieved number of cryovials per participant of each biological 
sample type is shown in Table 9.
Electronic data capture for all aspects of the health check was 
used to reduce data entry errors that occur when using paper 
forms. This included all interview responses as well as output 
from all measurement devices. In some cases the data files 
created by the devices were also automatically captured. Exceptions 
were measurement of height, waist and hip circumference, 
pulse oximetry and the physical function tests (grip strength, 
chair stands, standing balance) in which the values were entered 
via the keyboard. The processing of laboratory samples was 
also done using a bespoke sample handling application. Data 
capture software was created using SURVANT (Netelixis 
IT Solutions. SURVANT survey authoring and data collection 
software: version 1.0).
Detailed reports on data quality were created each month 
on key areas to be monitored such as characteristics of 
participants, GPS location of interviews, and inter-operator 
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Table 9. Target and achieved number of biological sample cryovials per participant.
Biological 
sample 
type
Sample 
collection
Target number of cryovials per participant by use Achieved 
mean number 
of cryovials 
/ participant 
among those 
who provided 
samples
Percentage of 
participants 
who provided 
at least one 
cryovial of each 
sample type for 
analysis*
Immediate 
feedback to 
participants
Local biobank 
in Arkhangelsk / 
Novosibirsk
Planned 
analyses in 
Moscow
Long-term 
biobank in 
Moscow
Total target 
number of 
cryovials
Serum
4 X SST II8.5 
ml Beckton 
Dickinson 
vacutainer
1 2 5 2 10 9.67 97.5
Plasma
1 X 10ml 
EDTA Becton 
Dickinson 
vacutainer
0 2 0 1 3 2.93 96.6
Whole blood
1 X 6ml 
EDTA Becton 
Dickinson 
vacutainer 
0 1 1 2 4 3.87 96.3
Urine 
Becton 
Dickinson urine 
collection pots
0 0 1 2 3 3.00 45.3
Faecal 
sample
Nuova Aptaca 
faecal sample 
collection pots
0 0 2 1 3 2.70 28.8
* Denominator was number of health check participants in both cities including all sub-studies. As the first serum cryovial was used for participant feedback it was 
not included in calculation
variability. These reports were reviewed by the central study 
team in a monthly meeting with immediate feedback provided 
to the fieldwork sites.
The questionnaires and data collection tools used in the study 
are shown in Supplementary File 3. These files show paper 
versions of the questions used however all data collections was 
done electronically (CAPI for the baseline questionnaire and 
SURVANT for the health check.)
Gut microbiome sub-study
The gut microbiome refers to digestive-tract associated microbes, 
and more than 1,000 microbial species-level phylotypes can 
be accessed by sequencing the 16S ribosomal RNA genic 
region of faecal DNA samples. An Imbalance of the normal gut 
microbiome has been linked with gastrointestinal conditions 
(e.g. Inflammatory bowel disease, Irritable bowel syndrome), 
systemic metabolic diseases (e.g. obesity, type 2 diabetes), and 
atopy, but underlying studies tend to have low sample size. 
Whilst, the microbiome is affected by factors such as age, 
antibiotic use, and diet, the composition of the microbiota is 
thought to be relatively stable within healthy adult individuals 
over time47. Within this study it is proposed to establish the rela-
tive abundance of microbes by 16S (V3-V4 region) sequenc-
ing of faecal samples (n=1000) collected in Arkhangelsk. 
The resulting characterization of the gut microbiome will be 
correlated with CVD outcomes, using regression-based asso-
ciation test that accounts for the rich set of confounders 
collected in the study. Analysis of the repeat samples collected 
a year later as part of the repeatability sub-study will facilitate 
an assessment of within-person microbiota stability over time. 
The presence of phylotypes that may be linked to cardiovascular 
outcomes will be confirmed using a metagenomic 
approach, where whole genomes, rather than targeted 16S, are 
characterized.
Comparison with Tromsø 7 “Heart to Heart Study”
The central objective of IPCDR is to understand why Russia 
has such high cardiovascular mortality compared to other 
countries. From the outset we planned to make comparisons 
of the cardiovascular phenotypes observed in Arkhangelsk and 
Novosibirsk with those observed in the 7th wave of the Tromsø 
study. To facilitate this comparison UiT, the Arctic University 
of Norway which runs the Tromsø study has created the Heart 
to Heart initiative which provides an umbrella under which 
this comparative scientific work can be developed.
The Tromsø Study is a population based survey of residents 
of the municipality of Tromsø in Northern Norway48. To date 
there have been 7 waves of data collection with the first wave 
starting in 1974. Tromsø, the largest city in Northern Norway 
and situated ~400km north of the Arctic Circle, is geographically 
close to Arkhangelsk and as such is a particularly interesting study 
with which to make international comparisons.
Data collection for the Tromsø 7 Study took place between 2015 
and 16 with a total of 21,000 men and women aged 40 and above 
living in Tromsø examined. During the development phases 
of both Tromsø 7 and the IPCDR Know Your Heart Study we 
aligned aspects of the medical examination and laboratory 
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analyses to make the data as comparable as possible. In particu-
lar an identical protocol was used for the ECHO measurements 
in both studies. A validation study has been carried out by the 
University Hospital of North Norway laboratories whereby split 
samples were analysed in Norway and in the Moscow laboratories 
used for conventional biochemistries. Some of the key areas for 
comparison between the Tromsø study and IPCDR studies are 
shown in Supplementary Table S4. The University Hospital in 
Tromsø has also undertaken a validation study to compare 
measurement of body composition using the two types of device 
used in each study. A similar validation study was done for the 
measurement of physical activity.
Data and statistical analysis plan
Data analyses will be focused around examining the asso-
ciations and comparisons of interest shown in Figure 1. The 
analysis plan consists broadly of two parts: analysis of asso-
ciations between key exposures of interest and cardiovascular 
phenotypes within Russia and 2) comparisons between Russia 
and other studies, particularly Tromsø 7. Examples of proposed 
analyses include: 
1)    Comparisons between Know Your Heart and Tromsø 
7 on cardiovascular risk factors such as blood 
pressure and body mass index will be carried out by 
calculating means for continuous variables and propor-
tions for categorical variables for all participants aged 
40–69 stratified by sex and age standardized to the 2013 
European Standard Population.
2)    One of our exposures of interest will be alcohol use. 
The data on self-reported consumption from the 
questionnaires and biomarker data (gamma glutamyl 
transferase, carbohydrate deficient transferrin for a 
sub-set) will be used to divide participants into appro-
priate groups (non-drinker, light drinker, moderate 
drinker, hazardous drinker (population sample), and 
hazardous drinker (diagnosed alcohol use disorder). 
Associations with cardiovascular disease phenotypes 
will be analysed using logistic and linear regression with 
adjustment for pre-specified confounders.
3)    Alongside well-established, clinical measures of car-
diovascular phenotype such as left ventricular ejection 
fraction, carotid intima media thickness (cIMT) and 
plaque, we are proposing to investigate whether there 
are underlying latent dimensions of cardiovascular 
phenotypes which can be obtained from the data using 
factor analysis.
A range of statistical analysis programs will be used including 
STATA (StataCorp LP), IBM SPSS stastistics (IBM Corporation) 
and R.
Discussion
Strengths and limitations
This study has collected very detailed data on cardiovascu-
lar profile and risk factors for cardiovascular disease from the 
general population of two geographically distinct cities within 
Russia. The close connection with the Tromsø 7 study allows 
for comparisons between Russia and Norway in the same 
calendar years with considerably less chance that differences 
are due to study methodology than many comparisons between 
population-based surveys. To our knowledge the inclusion 
of participants receiving treatment for alcohol problems in 
an in-depth study of cardiovascular phenotypes alongside 
a general population sample is unique. The use of the same 
tools and measurement procedures in both populations is an 
important strength of the study.
One of the potential limitations of the study is the low response 
rate for Novosibirsk. This creates uncertainty about the 
generalizability of study findings particularly around estimation 
of prevalences and mean values of parameters that will affect 
comparisons that can be made with other countries. In both sites 
response rates were higher in women and older people. 
However, non-response patterns were complex, and the extent 
to which they may limit inferences with the Tromsø 7 study 
will depend upon the direction and magnitude of the differ-
ences found. For example, the fact that in Novosibirsk the 
educational profile of participants was weighted more towards 
those with higher education than the population of the city 
as a whole, might be expected in many cases to minimize 
differences with Tromsø.
There are several possible reasons for the poorer response rates 
in Novosibirsk than Arkhangelsk. Novosibirsk is an appreciably 
larger city than Arkhangelsk, with citizens being potentially 
more suspicious of approaches to take part in research. 
The smaller size of Arkhangelsk was one of the factors that 
facilitated good links with the city government who provided 
extensive support for an intensive public information campaign 
about the study in the city that was on a larger and more 
sustained basis than in Novosibirsk. Finally, the smaller size of 
Arkhangelsk and the location of the research polyclinic in the 
center of the city made it easier for participants to attend than 
may have been the case in Novosibirsk.
Despite these limitations the richness of the data collected 
means there is an unparalleled opportunity for in-depth 
analysis of cardiovascular phenotypes and much greater under-
standing of how these are associated with a wide range of 
biological, psychological and socio-economic risk factors within 
Russia and with the Tromsø 7 study (Figure 1).
While this study was designed as a cross-sectional study consent 
for recontacting participants and accessing health records was 
obtained therefore there is potential to obtain follow up data in 
the future.
Dissemination of information
Bona fide researchers will be able to apply for subsets of the 
data from this study for research purposes. In addition, we 
are establishing a biobank of the biological samples collected 
in Russia. Researchers will be able to apply to analyse these 
samples within Russia. Further information about the study 
including details of how to access data and samples will 
be available at https://knowyourheart.science/ [active from 
June 2018]. This website will be updated from time to 
time with summaries of findings and links to a separate 
Page 21 of 29
Wellcome Open Research 2018, 3:67 Last updated: 04 DEC 2018
Supplementary material
Supplementary File 1: Promotional video shown on locally on TV (Arkhangelsk version)
Click here to access the data.
Supplementary File 2: Promotional materials (billboard advertisements) used to advertise the study within each city 
and photographs
Click here to access the data.
Supplementary File 3: Questionnaires and data collection tools. These are paper versions of the questions used however all data entry 
was done electronically 
Click here to access the data.
Supplementary File 4: Supplementary Tables (S1–S4) 
Click here to access the data.
Supplementary Table S1: Codes used for recording the outcome of visits to addresses
Supplementary Table S2: Health Check response percentages by age, sex and city
Supplementary Table S3: Associations between selected characteristics at baseline interview and not having a health check
Supplementary Table S4: Potential areas of comparison between Tromsø 7 and International Project on Cardiovascular Disease in 
Russia (IPCDR) Know Your Heart Study
meta-data website documenting all variables available. Dissemi-
nation of the study findings will be through publishing in peer 
reviewed journals, presenting at conferences within Russia and 
internationally and though meetings with policy makers.
Study status
Data collection for the study is completed. Data cleaning is 
now underway and key analyses are in process.
Data availability
No data is associated with this article.
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No new comments
 No competing interests were disclosed.Competing Interests:
Referee Expertise: epidemiology
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
Version 2
 03 August 2018Referee Report
https://doi.org/10.21956/wellcomeopenres.16005.r33447
 Zhengming Chen
Nuffield Department of Population Health, University of Oxford, Oxford, UK
The protocol paper by Sarah Cook and colleagues described rationale, design and conduct of a
cross-sectional study in Russia for in-depth investigation into CVD phenotypes and their associations with
a wide range of socio-economic, psychological and biological factors. The paper was well structured and
well written, with all the necessary details provided and major design, operational and analytic issues
discussed. Given the extremely high burden of cardiovascular disease in Russia and lack of proper
understanding about underlying risk factors in driving the high disease rates, the project is very timely and
will shed new light not only on epidemiology of CVD in Russia but also on roles of emerging and novel risk
factors in aetiology of CVD in general.
 
The project was well designed and conducted, with for example use of electronic data capture system to
minimise data entry error and ensure completeness. Although the overall response rate was not
particularly high, which is not uncommon for this type of community-based study, the completeness of the
data collection, particularly those related to physical examination and sample collection, among the
participants was extremely high. Moreover, most of the samples collected were processed within two
hours of the collection. There are also procedures in place for data access and collaboration with wider
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hours of the collection. There are also procedures in place for data access and collaboration with wider
research community. I only have a few minor comments that may further improve the manuscript.
It would be helpful to provide a map of Russia showing the geographical locations of the two cities
involved in the study, along with capital city Moscow;
 
In the analysis plan, the authors listed three possible areas of work and mentioned specifically left
ventricular ejection fraction but not cIMT/plaque measured by carotid ultrasound. cIMT and plaque
are commonly used surrogate endpoints for CVD. As such, it would be helpful to see them
highlighted specifically in the paper as a research priority.
 
 Although the study was designed to be a cross-sectional survey, it would be helpful to mention
briefly whether there is any plan to follow up participants long-term for cause-specific mortality and
other health outcomes. If not, then possible reasons for not doing so (eg, lack of power, problem
with linkages) should be discussed.
 
Overall this is a well written paper on a major new study that will throw new light on CVD aetiology
and epidemiology in Russia where there is substantial unmet need. I have no reservation in
recommending indexing.
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Yes
 No competing interests were disclosed.Competing Interests:
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
Author Response 21 Nov 2018
, London School of Hygiene & Tropical Medicine, UKSarah Cook
We would like to thank Professor Chen very much for his review.
In response to his comments we have made the following changes:
Map showing the location of the cities has been added (Figure 2)
We agree with the comment about the importance of carotid intima media thickness and
plaque as surrogate endpoints for CVD have added cIMTand plaque as areas of special
interest alongside left ventricular ejection fraction.
Discussion on the possibilities for follow up has been added to the discussion section.
 NoneCompeting Interests:
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 01 August 2018Referee Report
https://doi.org/10.21956/wellcomeopenres.16005.r33471
 Filip Zemrak
St. Bartholomew's Hospital, London, UK
Thank you for the clarifications. I am looking forward to seeing the results.
 No competing interests were disclosed.Competing Interests:
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
Version 1
 04 July 2018Referee Report
https://doi.org/10.21956/wellcomeopenres.15917.r33379
 Filip Zemrak
St. Bartholomew's Hospital, London, UK
This paper described the rationale, design and the protocol of a cross-sectional study of cardiovascular
disease in Russia.
Major comments
The sample size may not be large enough to describe phenotypes and their associations.
 
The variability of measurements (i.e. echo parameters, ECG) and the measurement techniques
(multiple centres, various scales, sphygmometers etc) will be significant.
 
Even with a much more reproducible method (cardiac MRI) in MESA study, which had a similar
sample size, the EF was not the best parameter to assess cardiac function/phenotype.
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Partly
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Not applicable
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 Not applicable
 No competing interests were disclosed.Competing Interests:
Referee Expertise: The authors should recognise that the study may not find associations of risk factors
to phenotypes as the sample size is too small.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
Author Response 04 Jul 2018
, London School of Hygiene & Tropical Medicine, UKSarah Cook
We thank Dr Filip Zemrak for his comments. Our response is as follows:
1. One of the major objectives of this study is to make comparisons between the Know Your Heart
Study in Russia and the Tromsø 7 Study, Norway. Dr Zemrak may wish to note that as shown in
Table 2 of our paper there are 8-10 fold differences in risk of CVD and IHD death between the
Russian and Norwegian populations. This is the background against which we are attempting to
identify differences in CVD phenotypes and risk factors. It is the basis for our confidence that even
our relatively small study (compared to for example UK Biobank or China Kadoorie Biobank) we
will find large differences in some key factors as a result. This has been supported by early findings
on interim data where we compared cardiovascular risk factors between the two studies. We found
strong evidence (i.e. very low p-values) for a difference between the study populations on several
of the key parameters of interest (e.g. blood pressure). These results were presented at Regional
Health Research Conference, Norway (2016) and the Russian National Congress of Cardiology
(2017). A full paper reporting these contrasts is in preparation now that all field work is completed.
Given the nature of the study (breadth of measures collected) it is not feasible to provide sample
size calculations for every possible research question of interest and the sample size calculations
given within the paper are designed to cover a range of plausible relevant scenarios. Our paper is a
study protocol describing the methodology of the study and providing key information about its
conduct and recruitment of subjects. To this extent the imprecision of any effect estimates we
subsequently report will be reflected in the confidence intervals. We agree with Dr Zemrak that for
some things we will be underpowered, whether this is in comparisons with other studies such as
the Tromsø study, or comparisons within the Russian study populations. However, for other things
we will be more than adequately powered. We have acknowledged this limitation in the revised
version of the paper.
 
2. We acknowledge measurement error is a limitation as in any multi-site epidemiological study. As
outlined in the paper several steps were taken to minimize variability including the production of
detailed standard operating procedures, review of reports on data quality every month throughout
the duration of the fieldwork and regular assessment of intra- and inter- reader variability in offline
reading of ECHO and vascular ultrasound data. A strength of the study design (as described within
the paper) is that in each city a further 200 participants were invited back one year after their initial
health check and completed all study procedures for a second time.  From this data we have been
able to calculate correction factors which assess the extent of within-person variability in
measurements (which includes measurement error due to factors such as variation in observers
and devices). From a further paper (currently under review) we can demonstrate our correction
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 and devices). From a further paper (currently under review) we can demonstrate our correction
factors for a variety of measures are comparable (and generally lower) to those from a very large
“gold standard” UK study providing additional reassurance on data validity. Given that this paper is
a protocol paper it would not be appropriate to include these more substantive results concerning
repeatability of measures. These will be published alongside results of specific analyses as they
appear. 
3. Ejection fraction is not the main or only functional parameter of interest in this study. Others are
described in the protocol under details of the health check examination. We mentioned ejection
fraction under our illustrative analysis plan as an example of a commonly used parameter within
clinical practice which may be used alongside more agnostic methods such as factor analysis but it
was not our intention to suggest this is the only parameter to be investigated. As we describe in the
protocol paper we are undertaking intra- and inter-site reliability studies of off line reading.
Unfortunately we did not have the resources to undertake cardiac MRI on 4500 Russian
participants and equivalent number of Norwegian study subjects. 
 NoneCompeting Interests:
 21 June 2018Referee Report
https://doi.org/10.21956/wellcomeopenres.15917.r33258
 John Lynch
School of Population Health, University of Adelaide, Adelaide, SA, Australia
This is a ‘model’ example of how a protocol paper should be written. The protocol is exceptionally clearly
written and contains all the necessary details of the various study aspects including the study purpose,
sampling, recruitment and the various dimensions of data collection, through to an outline of the analysis
plan.
 
It requires no revisions and can be published as it stands.
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Yes
 No competing interests were disclosed.Competing Interests:
Referee Expertise: Epidemiology
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it is of an acceptable scientific standard.
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